BR112018073660A2 - anticorpos anti-fator ix pádua - Google Patents
anticorpos anti-fator ix páduaInfo
- Publication number
- BR112018073660A2 BR112018073660A2 BR112018073660-0A BR112018073660A BR112018073660A2 BR 112018073660 A2 BR112018073660 A2 BR 112018073660A2 BR 112018073660 A BR112018073660 A BR 112018073660A BR 112018073660 A2 BR112018073660 A2 BR 112018073660A2
- Authority
- BR
- Brazil
- Prior art keywords
- factor
- antibodies
- padua
- conjugates
- paddle
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/005—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies constructed by phage libraries
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/35—Valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
- C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
- C07K2319/43—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a FLAG-tag
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
- G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
- G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
- G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
- G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
- G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
- G01N2333/96433—Serine endopeptidases (3.4.21)
- G01N2333/96441—Serine endopeptidases (3.4.21) with definite EC number
- G01N2333/9645—Factor IX (3.4.21.22)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Urology & Nephrology (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- General Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biophysics (AREA)
- Virology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662337118P | 2016-05-16 | 2016-05-16 | |
| US62/337,118 | 2016-05-16 | ||
| US201662340834P | 2016-05-24 | 2016-05-24 | |
| US62/340,834 | 2016-05-24 | ||
| PCT/US2017/032808 WO2017200981A1 (en) | 2016-05-16 | 2017-05-16 | Anti-factor ix padua antibodies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112018073660A2 true BR112018073660A2 (pt) | 2019-02-19 |
Family
ID=59067875
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112018073660-0A BR112018073660A2 (pt) | 2016-05-16 | 2017-05-16 | anticorpos anti-fator ix pádua |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US11098132B2 (enExample) |
| EP (1) | EP3458477B1 (enExample) |
| JP (3) | JP7084878B2 (enExample) |
| KR (2) | KR102481704B1 (enExample) |
| CN (1) | CN109563154B (enExample) |
| AU (1) | AU2017268198C1 (enExample) |
| BR (1) | BR112018073660A2 (enExample) |
| CA (1) | CA3024485A1 (enExample) |
| IL (1) | IL262813B2 (enExample) |
| RU (2) | RU2022108606A (enExample) |
| SG (1) | SG11201809642TA (enExample) |
| WO (1) | WO2017200981A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201709970D0 (en) | 2017-06-22 | 2017-08-09 | Kymab Ltd | Bispecific antigen-binding molecules |
| CN110343181B (zh) * | 2018-04-08 | 2022-04-08 | 苏州康宁杰瑞生物科技有限公司 | 针对凝血因子ix(fix)的单域抗体 |
| WO2020128049A1 (en) | 2018-12-21 | 2020-06-25 | Kymab Limited | Fixaxfx bispecific antibody with common light chain |
| GB202009928D0 (en) * | 2020-06-29 | 2020-08-12 | Freeline Therapeutics Ltd | Method |
| US12098400B2 (en) * | 2022-07-08 | 2024-09-24 | Novo Nordisk A/S | Highly potent ISVD compounds capable of substituting for FVIII(A) |
| CN118834275A (zh) * | 2023-02-07 | 2024-10-25 | 湖南九典制药股份有限公司 | 一种抗菌/抗炎多肽及其用途 |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3691016A (en) | 1970-04-17 | 1972-09-12 | Monsanto Co | Process for the preparation of insoluble enzymes |
| CA1023287A (en) | 1972-12-08 | 1977-12-27 | Boehringer Mannheim G.M.B.H. | Process for the preparation of carrier-bound proteins |
| US4195128A (en) | 1976-05-03 | 1980-03-25 | Bayer Aktiengesellschaft | Polymeric carrier bound ligands |
| US4330440A (en) | 1977-02-08 | 1982-05-18 | Development Finance Corporation Of New Zealand | Activated matrix and method of activation |
| CA1093991A (en) | 1977-02-17 | 1981-01-20 | Hideo Hirohara | Enzyme immobilization with pullulan gel |
| US4229537A (en) | 1978-02-09 | 1980-10-21 | New York University | Preparation of trichloro-s-triazine activated supports for coupling ligands |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| JP2938569B2 (ja) | 1990-08-29 | 1999-08-23 | ジェンファーム インターナショナル，インコーポレイティド | 異種免疫グロブリンを作る方法及びトランスジェニックマウス |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5780279A (en) | 1990-12-03 | 1998-07-14 | Genentech, Inc. | Method of selection of proteolytic cleavage sites by directed evolution and phagemid display |
| WO1992009690A2 (en) | 1990-12-03 | 1992-06-11 | Genentech, Inc. | Enrichment method for variant proteins with altered binding properties |
| US5871907A (en) | 1991-05-15 | 1999-02-16 | Medical Research Council | Methods for producing members of specific binding pairs |
| US6225447B1 (en) | 1991-05-15 | 2001-05-01 | Cambridge Antibody Technology Ltd. | Methods for producing members of specific binding pairs |
| US5858657A (en) | 1992-05-15 | 1999-01-12 | Medical Research Council | Methods for producing members of specific binding pairs |
| US5234784A (en) | 1992-04-01 | 1993-08-10 | Eastman Kodak Company | Method of making a projection viewable transparency comprising an electrostatographic toner image |
| US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
| US5855885A (en) | 1993-01-22 | 1999-01-05 | Smith; Rodger | Isolation and production of catalytic antibodies using phage technology |
| US5702892A (en) | 1995-05-09 | 1997-12-30 | The United States Of America As Represented By The Department Of Health And Human Services | Phage-display of immunoglobulin heavy chain libraries |
| US6699843B2 (en) | 1995-06-07 | 2004-03-02 | Gilead Sciences, Inc. | Method for treatment of tumors using nucleic acid ligands to PDGF |
| US6265150B1 (en) | 1995-06-07 | 2001-07-24 | Becton Dickinson & Company | Phage antibodies |
| US5714352A (en) | 1996-03-20 | 1998-02-03 | Xenotech Incorporated | Directed switch-mediated DNA recombination |
| DK0826696T3 (da) | 1996-09-03 | 2002-09-23 | Gsf Forschungszentrum Umwelt | Anvendelse af bi- og trispecifikke antistoffer til inducering af en tumorimmunitet |
| US6057098A (en) | 1997-04-04 | 2000-05-02 | Biosite Diagnostics, Inc. | Polyvalent display libraries |
| AT411997B (de) | 1999-09-14 | 2004-08-26 | Baxter Ag | Faktor ix/faktor ixa aktivierende antikörper und antikörper-derivate |
| EP1257289A1 (en) | 2000-02-08 | 2002-11-20 | The Penn State Research Foundation | Immunotherapy using interleukin 13 receptor subunit alpha 2 |
| DE60219419T2 (de) | 2001-01-19 | 2007-08-16 | Ludwig Institute For Cancer Research | Flt4 (vegfr-3) als ein ziel für krebsdarstellung und anti-krebs-behandlung |
| US20040096983A1 (en) * | 2002-11-14 | 2004-05-20 | Jacobs Merrit N. | Wash process for a sample being analyzed |
| JP2006524039A (ja) | 2003-01-09 | 2006-10-26 | マクロジェニクス，インコーポレーテッド | 変異型Ｆｃ領域を含む抗体の同定および作製ならびにその利用法 |
| TWI353991B (en) | 2003-05-06 | 2011-12-11 | Syntonix Pharmaceuticals Inc | Immunoglobulin chimeric monomer-dimer hybrids |
| US7297336B2 (en) * | 2003-09-12 | 2007-11-20 | Baxter International Inc. | Factor IXa specific antibodies displaying factor VIIIa like activity |
| US20050282233A1 (en) | 2004-03-05 | 2005-12-22 | Ludwig Institute For Cancer Research | Multivalent antibody materials and methods for VEGF/PDGF family of growth factors |
| EP2824183B1 (en) * | 2005-04-08 | 2020-07-29 | Chugai Seiyaku Kabushiki Kaisha | Methods for producing bispecific antibodies |
| US8234784B2 (en) | 2008-02-13 | 2012-08-07 | Younger Steven W | Valve piston repositioning apparatus and method |
| EP3542861A1 (en) * | 2012-09-25 | 2019-09-25 | Bioverativ Therapeutics Inc. | Methods of using fix polypeptides |
| DK2911687T3 (da) * | 2012-10-26 | 2019-05-13 | Univ Brussel Vrije | Vektor til levermålrettet genterapi af hæmofili og fremgangsmåder og anvendelse deraf |
| EP2881463A1 (en) | 2013-12-09 | 2015-06-10 | DRK-Blutspendedienst Baden-Württemberg-Hessen gGmbH | Factor IX variants with clotting activity in absence of their cofactor and/or with increased F.IX clotting activity and their use for treating bleeding disorders |
| WO2016004113A1 (en) | 2014-06-30 | 2016-01-07 | Biogen Ma Inc. | Optimized factor ix gene |
-
2017
- 2017-05-16 EP EP17730590.1A patent/EP3458477B1/en active Active
- 2017-05-16 RU RU2022108606A patent/RU2022108606A/ru unknown
- 2017-05-16 SG SG11201809642TA patent/SG11201809642TA/en unknown
- 2017-05-16 RU RU2018138782A patent/RU2770006C2/ru active
- 2017-05-16 CN CN201780044200.9A patent/CN109563154B/zh active Active
- 2017-05-16 AU AU2017268198A patent/AU2017268198C1/en active Active
- 2017-05-16 KR KR1020187036234A patent/KR102481704B1/ko active Active
- 2017-05-16 KR KR1020227044875A patent/KR102625416B1/ko active Active
- 2017-05-16 JP JP2018560082A patent/JP7084878B2/ja active Active
- 2017-05-16 US US16/301,962 patent/US11098132B2/en active Active
- 2017-05-16 WO PCT/US2017/032808 patent/WO2017200981A1/en not_active Ceased
- 2017-05-16 CA CA3024485A patent/CA3024485A1/en active Pending
- 2017-05-16 BR BR112018073660-0A patent/BR112018073660A2/pt active Search and Examination
-
2018
- 2018-11-06 IL IL262813A patent/IL262813B2/en unknown
-
2021
- 2021-08-17 US US17/404,459 patent/US11999798B2/en active Active
-
2022
- 2022-06-03 JP JP2022090787A patent/JP2022133276A/ja not_active Withdrawn
-
2024
- 2024-02-19 JP JP2024022760A patent/JP7671887B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP3458477B1 (en) | 2025-07-09 |
| IL262813B2 (en) | 2025-12-01 |
| JP2024056941A (ja) | 2024-04-23 |
| AU2017268198B2 (en) | 2020-09-03 |
| JP7084878B2 (ja) | 2022-06-15 |
| KR20230006026A (ko) | 2023-01-10 |
| AU2017268198A1 (en) | 2018-11-22 |
| RU2018138782A3 (enExample) | 2020-07-14 |
| IL262813B1 (en) | 2025-08-01 |
| KR102481704B1 (ko) | 2022-12-27 |
| AU2017268198C1 (en) | 2020-11-26 |
| KR102625416B1 (ko) | 2024-01-15 |
| JP2022133276A (ja) | 2022-09-13 |
| US20220056150A1 (en) | 2022-02-24 |
| SG11201809642TA (en) | 2018-11-29 |
| CN109563154A (zh) | 2019-04-02 |
| WO2017200981A1 (en) | 2017-11-23 |
| RU2770006C2 (ru) | 2022-04-14 |
| RU2018138782A (ru) | 2020-06-17 |
| CN109563154B (zh) | 2024-12-13 |
| JP7671887B2 (ja) | 2025-05-02 |
| KR20190006548A (ko) | 2019-01-18 |
| US11999798B2 (en) | 2024-06-04 |
| JP2019527033A (ja) | 2019-09-26 |
| RU2022108606A (ru) | 2022-04-11 |
| WO2017200981A8 (en) | 2018-02-01 |
| EP3458477A1 (en) | 2019-03-27 |
| NZ747752A (en) | 2025-05-30 |
| CA3024485A1 (en) | 2017-11-23 |
| IL262813A (en) | 2018-12-31 |
| US20190194351A1 (en) | 2019-06-27 |
| US11098132B2 (en) | 2021-08-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1120951T1 (el) | Ανθρωπινα αντισωματα enanti-tau | |
| BR112018073660A2 (pt) | anticorpos anti-fator ix pádua | |
| CY1125141T1 (el) | Εισαγωγη μεταβλητων θραυσματων αντισωματων και τροποποιημενοι τομεις α1-α2 των συνδετων nkg2d | |
| CY1123518T1 (el) | Ανθρωπινα αντισωματα enanti-tau | |
| CY1124118T1 (el) | Αντισωματα προσδεσης θυμικης στρωματικης λεμφοποιητινης (tslp) και μεθοδοι χρησης των αντισωματων | |
| CY1122676T1 (el) | Αντισωματα εναντι της κλαυδινης 18.2 που ειναι χρησιμα στη διαγνωση του καρκινου | |
| CO2018011364A2 (es) | Anticuerpos anti-il-33, composiciones, métodos y usos de los mismos | |
| BR112017020054A2 (pt) | anticorpos para icos | |
| CO2018005436A2 (es) | Anticuerpos y fragmentos de anticuerpo para la conjugación sitio-específica | |
| BR112019011186A2 (pt) | conjugado de anticorpo radiomarcado, composto, e, métodos de imageamento e para tratamento de um tumor. | |
| BR112018002844A2 (pt) | receptores de antígeno quimérico à base de anticorpos de domínio único e métodos de uso dos mesmos | |
| BR112018070260A2 (pt) | receptores quiméricos e métodos de uso dos mesmos | |
| EA201891709A1 (ru) | Антигенсвязывающие белки, связывающие pd-l1 | |
| CL2017000278A1 (es) | Moléculas biespecíficas de unión a antígeno activadoras de células t | |
| CR20240116A (es) | RECEPTORES QUIMÉRICOS DE FLT3 Y MÉTODOS DE USO DE LOS MISMOS (Divisional 2018-518) | |
| WO2017004026A8 (en) | Anti-cd123 antibodies and conjugates and derivatives thereof | |
| DK2681244T3 (da) | Cea-antistoffer | |
| BR112015022490A2 (pt) | métodos e composições para classificação de amostras | |
| BR112014028785A2 (pt) | proteínas de ligação a antígeno de st2 | |
| EP3587439A3 (en) | Improved quantification of vaccine compositions | |
| MX365387B (es) | Anticuerpos específicos de polipéptido amiloide de islote humano (hiapp) y sus usos. | |
| BR112016024515A2 (pt) | proteínas do agonista do receptor trail de cadeia única | |
| BR112017006598A2 (pt) | anticorpo de repetições antidipeptídeo derivado de ser humano (dprs) | |
| EA202091350A1 (ru) | Связывающие молекулы, специфично связывающиеся с тау-белком | |
| EA201791691A1 (ru) | ОДНОДОМЕННЫЕ АНТИТЕЛА, НАПРАВЛЕННЫЕ НА CD1d |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
| B25A | Requested transfer of rights approved |
Owner name: TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) |
|
| B25K | Entry of change of name and/or headquarter and transfer of application, patent and certificate of addition of invention: republication |
Owner name: TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) Free format text: RETIFICACAO DO DESPACHO (25.1) ? TRANSFERENCIA DE TITULAR PUBLICADO NA RPI NO 2651, DE 26/10/2021, QUANTO A PETICAO.ONDE SE LE: 870210065492 DE 19/07/2021LEIA-SE: 870210065495 DE 19/07/2021 |
|
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] | ||
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] |